Jude A. is a bioinformatician at the National Center for Tumor Diseases (NCT) Heidelberg since January 2021, focusing on data analysis for the MASTER precision oncology program. Previously, Jude served as a postdoctoral researcher at the DKFZ German Cancer Research Center, implementing spatial transcriptomics technologies for human bone marrow in myeloma studies. As a PhD candidate at HI-STEM/DKFZ from October 2016 to August 2020, Jude developed methods for analyzing bone marrow architecture with single-cell RNA sequencing and investigated hematopoietic stem cell heterogeneity. Prior experience includes work as a research associate at Indiana University, studying circadian dysregulation in diabetic retinopathy, and as a visiting researcher at the University of Florida, exploring molecular mechanisms behind diabetic retinopathy. Jude holds a PhD from DKFZ German Cancer Research Center and a Master’s degree in Molecular Biotechnology from Heidelberg University.
National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.